As part of the collaboration, the parties will use BioSymetrics’ Contingent-AI™ engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease.
BioSymetrics CSO Gabe Musso to Present on Artificial Intelligence and Machine Learning for Biomedical R&D Innovation at the 2019 BIO International Convention
PHILADELPHIA – (June 3, 2019) – Biomedical artificial intelligence (AI) company BioSymetrics will offer a presentation on the use of AI and machine learning for healthcare and biomedical R&D innovation at the 2019 BIO International Convention, which is being held June 3-6 at the Pennsylvania Convention Center in Philadelphia. The company’s Chief Scientific Office, Gabe Musso, will lead the presentation on Wednesday, June 5, at 11:15 am, in Theater 3. Continue Reading
Advocate for healthcare technology innovation joins BioSymetrics in a mission to empower the application of AI within biomedicine.
NEW YORK, February 7, 2019 (GLOBE NEWSWIRE) – BioSymetrics, an artificial intelligence and machine learning SaaS company, announces Dr. Calum MacRae as Senior Advisor. Dr. MacRae is an innovative pioneer in genetics, biology, and drug discovery. With his deep knowledge and expertise, Dr. MacRae will assist BioSymetrics in the design and application of the company’s software for use in drug discovery, precision medicine and health systems.
“The introduction of AI into medicine is challenged by a fundamental defect of information content and standards,” said Dr. Calum MacRae. “BioSymetrics is leading the promise that we are entering an era in which precision medicine and AI finally attain real world applications; overcoming a number of AI challenges across a wide spectrum of biomedicine.” Continue Reading